Key result
Exogenous phosphocreatine linked to ~82% lower postoperative morbidity in elderly colorectal cancer patients.
Why the study?
The efficacy of exogenous phosphocreatine application in elderly and senile patients operated for colorectal cancer was evaluated due to uncertainty about its impact on postoperative morbidity.
Does exogenous phosphocreatine reduce postoperative morbidity in elderly patients operated for colorectal cancer?
Cohort (n=136)
Does exogenous phosphocreatine reduce postoperative morbidity in elderly patients operated for colorectal cancer?
Odds Ratio: 0.18 (95% CI 0.07–0.49)
Absolute Event Rate: 7.2% vs 35%
p-value: p=0.001
Exogenous phosphocreatine supplementation during perioperative management may significantly reduce postoperative morbidity, including acute coronary syndrome, in elderly patients undergoing colorectal cancer surgery.
Should not yet change perioperative practice in elderly colorectal cancer patients; leaves open efficacy pending randomized trials.
Objective : to evaluate the efficacy of exogenous phosphocreatine (EPCr) application in elderly and senile patients operated for colorectal cancer. Material and methods . 80 patients with routine perioperative management (Group 1) and 56 patients in whom routine perioperative management was supplemented with EPCr administration (Group 2). Postoperative morbidity and duration of hospitalization after surgery have been assessed in both groups. Results . Postoperative morbidity was lower in Group 2: 7.2% vs. 35% (P=0.001; OR=0.18; 95% CI: 0.07—0.49), mainly due to decreasing the incidence of acute coronary syndrome and anastomotic leakage. The duration of hospi% talization after surgery was lower in Group 2 as well. Conclusions . Application of EPCr might be an effective measure to decrease the postoperative morbidity in elderly and senile patients with colorectal cancer.
No takes yet. Share an insight, caveat, or question.
Derbugov et al. (2017) conducted a cohort in Colorectal cancer (n=136). Exogenous phosphocreatine (EPCr) vs. Routine perioperative management was evaluated on Postoperative morbidity (OR 0.18, 95% CI 0.07-0.49, p=0.001). Exogenous phosphocreatine supplementation reduced postoperative morbidity in elderly patients operated for colorectal cancer compared to routine management (7.2% vs. 35%; OR 0.18; 95% CI 0.07-0.49).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: